Hepta

Hepta detects chronic disease early by using cfDNA epigenetic analysis and AI to deliver accurate, non-invasive diagnostics at population scale. Founded by former Illumina, Grail and Google scientists, the company is backed by Felicis Ventures, Illumina Ventures, SeaX Ventures, Alumni Ventures, and AME Cloud Ventures. Hepta is proving that blood-based epigenetic biomarkers can replace invasive biopsies, enabling earlier and more accessible detection of diseases like MASH and laying the foundation for future applications across chronic diseases.

Content by Hepta

Image of a clinician in the background interacting with a graphic of the liver and other medicine-related icons

Mapping MASH: Understanding Liver Disease from Blood Samples

By The Scientist and Hepta | | 5 min read

Page 1 of 1 - 1 Total Items

September 2026

Multiplex Microscopy Becomes Easier with Encoded Antibodies

A new system that enables researchers to uniquely tag monoclonal antibodies for use in microscopy could help simplify complex imaging studies.

View this Issue

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Rethinking ALS Biomarkers: From Discovery to Clinical Impact

Explore how emerging biomarker research and ultrasensitive multiplex proteomics are revealing molecular signatures associated with neurodegeneration, inflammation, and disease progression in amyotrophic lateral sclerosis (ALS).

Best Practices for qPCR Assay Design and Optimization

Explore practical strategies for designing, optimizing, and validating qPCR assays to improve specificity, reproducibility, and confidence across routine and high-throughput gene expression studies.

Beyond the Basics: Strategies for Single-Cell and Spatial Transcriptomics Analysis

Explore strategies for navigating critical analytical decisions in single-cell RNA sequencing and spatial transcriptomics, from quality control and data integration to clustering, marker selection, and cell-type annotation.

Scientist reviewing cellular and molecular data on a computer in a laboratory.

Building Translation-Ready Biomarkers with Connected Workflows

Identify sources of variability and approaches for improving consistency across biomarker development.